Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease

Sclerotic skin manifestations of chronic graft-versus-host disease (ScGVHD) lead to significant morbidity, including functional disability from joint range of motion (ROM) restriction. No superior second-line therapy has been established for steroid-refractory disease. Imatinib mesylate is a multi-k...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Biol Blood Marrow Transplant
Päätekijät: Baird, Kristin, Comis, Leora E., Joe, Galen O., Steinberg, Seth M., Hakim, Fran T., Rose, Jeremy J., Mitchell, Sandra A., Pavletic, Steven Z., Figg, William D., Yao, Lawrence, Flanders, Kathleen C., Takebe, Naoko, Sarantopoulos, Stefanie, Booher, Susan, Cowen, Edward W.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2015
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4425991/
https://ncbi.nlm.nih.gov/pubmed/25771402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2015.03.006
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia